Close navigation

Diffuse midline glioma research

Diffuse intrinsic pontine glioma (DIPG), now known as Diffuse Midline Glioma (DMG), is a type of brain tumour that forms in a part of the brainstem known as the pons. DIPG affects between 20 to 30 children in the UK every year and there is no effective treatment.

Diffuse intrinsic pontine glioma tumours are incredibly difficult to treat as they can't be be operated on due to their location within the brainstem, a crucial part of the brain that controls vital functions such as breathing. Our researchers are determined to understand more about this condition and develop new and effective methods to treat it.

Current DIPG/DMG research projects

Here are the research projects we are currently funding that relate to understanding or treating diffuse midline glioma (formerly known as DIPG)

Dr Darren Hargrave

Tumour-targeted drugs tested in children with high grade brain tumours

share this

Dr Darren Hargrave

New clinical trials for children with DIPG

Dr Darren Hargrave, a paediatric neuro-oncologist at Great Ormond Street Hospital, is leading a new clinical trial testing three new drugs in 150 children affected by DIPG. This trial will investigate whether each of these new drugs are effective when combined with radiotherapy, whether they can treat the tumour and whether they are well tolerated by patients. The study will be carried out over five years and is being funded in partnership with Cancer Research UK.

Find out more

share this

Dr Adrian Bracken

Finding new methods to treat Diffuse Midline Glioma

share this

Dr Adrian Bracken

Finding new methods to treat Diffuse Midline Glioma

Dr Adrian Bracken and his research team at Trinity College Dublin aim to develop new methods to treat diffuse midline glioma, formerly known as Diffuse Intrinsic Pontine Glioma (DIPG).

Previous research has demonstrated that the regulation of chromatin is disrupted in various cancers. Chromatin regulation refers to the process of DNA being wrapped around special proteins called histones. The research team will be focusing on finding new ways to block the activity of a particular protein involved in chromatin deregulation.

Find out more

share this

Current high grade, child brain tumour research projects

Here are some other research projects we are currently funding that relate to understanding or treating high grade child brain tumours including diffuse midline glioma (formerly known as DIPG)

Prof. Steve Clifford

INSTINCT:on a mission to beat childhood brain tumours

share this

Professor Steve Clifford

INSTINCT - a pioneering research programme for DIPG

Our INSTINCT programme brings together experts from Newcastle University, the Institute of Cancer Research (ICR) and the UCL Institute for Child Health in London to research high-risk childhood brain tumours, including DIPG.

The research programme on DIPG is being led by Dr Chris Jones at the Institute of Cancer Research. Dr Jones has extensive experience in understanding the genetic basis of these tumours and what is driving tumour growth and then developing new drugs that target the genes involved. In recognition of Dr Jones' expertise in this field, he is Chair of the European Society of Paediatric Oncology's group on DIPG and high-grade paediatric brain tumours. As part of the collaborative aims of INSTINCT Dr Jones, with the support of The Brain Tumour Charity, is hosting a closed meeting for some of the world leading experts in DIPG. The aims of the meeting are to combine knowledge and scientific findings from around the world to make faster breakthroughs in DIPG research.

Find out more

share this

Prof. Colin Watts

Tessa Jowell BRAIN MATRIX

share this

Professor Colin Watts

Tessa Jowell BRAIN MATRIX

The Tessa Jowell BRAIN-MATRIX is a first-of-its-kind clinical trial that will enable doctors to treat brain tumours with drugs that are more targeted than ever before. We are excited to be investing £2.8 million to set the trial up, and to drive it into the future.

Although the trial is being led from the UK, we expect it to deliver global impact for brain cancer patients.

Find out more

share this

Prof. Colin Kennedy

The PROMOTE Study

share this

Professor Colin Kennedy

The PROMOTE Study

The project is named The PROMOTE Study - Patient Reported Outcome Measures Online To Enhance Communication and Quality of Life after childhood brain tumour.

The PROMOTE team are developing an online programme called KLIK which will be used by children and their families to keep track of any issues they have between consultations.

This research will propel our ability to understand, and potentially prevent, the harsh side effects of brain tumour treatment in children to help accelerate a change for those affected.

Find out more

share this

Prof. Terrance Johns

Preventing resistance to targeted therapies

share this

Professor Terrance Johns

Preventing resistance to targeted therapies

Despite aggressive treatment with surgery, radiotherapy and chemotherapy, patients with HGGs have an extremely poor prognosis.

A number of targeted therapies have also been tested but have failed to improve outcomes for these patients, highlighting the urgent need to better understand the biology of these tumours and why treatments fail.

This research aims to identify new drug combinations that are more effective and may improve survival for patients with HGGs. And by using treatments that are already approved and used in clinical practice, this process will be dramatically sped up.

Find out more

share this

Working on links with other diseases

Dr Chris Jones and his team at the ICR have previously found a common genetic fault in the DNA of some children with DIPG and the DNA of people with fibrodysplasia ossificans progressive (FOP). Sometimes called Stone Man Syndrome, FOP causes damaged muscle to turn to bone, so that patients experience increasing immobility and pain as they are gradually 'locked in' to a growing skeleton. Scientists have already discovered that FOP is caused by a fault in the gene ACVR1, which is also found in some DIPG patients. Some of the drugs being developed to treat FOP have also shown to be effective in killing tumour cells containing the ACVR1 fault.